A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
The study, led by Kevin Nead, M.D., assistant...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...
The University of Texas MD Anderson Cancer Center again has been named No. 1 in cancer in the U.S. News & World Report’s 2021-2022 annual “Best Hospitals” rankings. Since the ranking's inception in 1990, the institution has been selected as one of the top two hospitals for cancer in the country.
“This year’s ranking is especially rewarding considering the exceptional teamwork and collaboration we have seen throughout our...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab...
A Phase II cohort from the international PIVOT-02 study has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin...
The University of Texas MD Anderson Cancer Center and Hummingbird Bioscience today announced the launch of a multi-year strategic research...
Researchers from The University of Texas MD Anderson Cancer Center found specific intestinal microbiota signatures correlate with high-grade...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published ...